OIS@AAO 2019

 Antony Mattessich of Ocular Therapeutix discusses the company’s first launch (Dextenza), the ins and outs of drug delivery technology and formulations, and what the…

Public gene therapy company Adverum Biotechnologies’ Aaron Osborne, MBBS MRCOpth, discusses ADVM-022, an intravitreal gene therapy for VEGF-driven retinal diseases. Aaron Osborne, MD, Chief Medical…

SightGlass Vision’s Joe Rappon details the “simple and achievable” idea that will revolutionize how to treat/prevent myopia, along with details on CYPRESS, the pivotal p3…



Jim Mazzo of Carl Zeiss Meditec talks all things innovation, from the role of digitization to make physicians more productive to reimbursement rates to where…

Patrik De Haes, MD, CEO speaks for Oxurion during the Public Company Spotlight at OIS@AAO 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv.

Vertical Pharma’s David Jacobs, MD, MBA, talks about RVL-1201, the first topical drop to treat blepharoptosis during the Innovative Showcase at OIS@AAO 2019. REGISTER for…

In a one-on-one, Todd C. Brady, MD, PhD, talks with OIS@AAO’s Ehsan Sadri, MD, FACS, about reactive aldehyde species (RASP) — reactive molecules that covalently…

Nancy Lurker, President & CEO speaks for EyePoint Pharmaceuticals during the Public Company Spotlight at OIS@AAO 2019. REGISTER for our next ophthalmology conference today.